Ciltacabtagene autoleucel Recruiting Phase 3 Trials for Multiple Myeloma (MM) Treatment

RecruitingTreatment3 IdentifierTitleDrugs
NCT04923893A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy